Genprex announces presentations on Reqorsa Gene Therapy at 2026 AACR

Genprex (GNPX) announced that its research collaborators presented at the 2026 American Association for Cancer Research, or AACR, Annual Meeting being held April 17-22 in San Diego, California. The collaborators presented positive preclinical data from studies of its lead drug candidate, Reqorsa Gene Therapy, for the treatment of lung cancer. The featured Genprex-supported abstracts and posters presented at AACR 2026 are: “TROP2 and PTEN are biomarkers of primary resistance to TUSC2 gene therapy in non-small cell lung cancer”; “Quaratusugene ozeplasmid mediated TUSC2 upregulation in EML4-ALK bearing non-small cell lung carcinoma induces apoptosis and is highly effective in preclinical studies”; “Restoring TUSC2 function boosts NK cell cytotoxicity and antitumor immunity in vivo and in vitro”.